These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17334198)

  • 1. Managing common Side effects of SSRIs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 Feb; 45(2):15-8. PubMed ID: 17334198
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
    Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
    CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of selective serotonin reuptake inhibitors.
    Goldberg RJ
    Arch Fam Med; 1999; 8(3):196-7. PubMed ID: 10333810
    [No Abstract]   [Full Text] [Related]  

  • 4. A Paradigmatic Case of Postselective Serotonin Reuptake Inhibitors Sexual Dysfunction or Withdrawal After Discontinuation of Selective Serotonin Reuptake Inhibitors?
    Patacchini A; Cosci F
    J Clin Psychopharmacol; 2020; 40(1):93-95. PubMed ID: 31834096
    [No Abstract]   [Full Text] [Related]  

  • 5. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Can J Psychiatry; 2006 Oct; 51(12):783-90. PubMed ID: 17168253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.
    Anderson HD; Pace WD; Libby AM; West DR; Valuck RJ
    Clin Ther; 2012 Jan; 34(1):113-23. PubMed ID: 22177545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switching to milnacipran.
    Takahashi H; Ishigooka J
    Clin Neuropharmacol; 2009; 32(3):177-8. PubMed ID: 19483494
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical relevance of antidepressant-induced activation syndrome: from a perspective of bipolar spectrum disorder].
    Tanaka T; Inoue T; Suzuki K; Kitaichi Y; Masui T; Denda K; Koyama T
    Seishin Shinkeigaku Zasshi; 2007; 109(8):730-42. PubMed ID: 17969991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Janu-faced serotonergic antidepressant nature: mental versus sexual health!
    Calabrò RS
    Gen Hosp Psychiatry; 2015; 37(3):e9. PubMed ID: 25802169
    [No Abstract]   [Full Text] [Related]  

  • 10. Limitations of contemporary antidepressants: tolerability.
    Papakostas GI
    J Clin Psychiatry; 2007; 68 Suppl 10():11-7. PubMed ID: 17900204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of brain-derived neurotrophic factor valine to methionine polymorphism with sexual dysfunction following selective serotonin reuptake inhibitor treatment in female patients with major depressive disorder.
    Nazree NE; Mohamed Z; Reynolds GP; Mohd Zain S; Masiran R; Sidi H; Chong LA; Hway AY; Adlan AS; Zainal NZ
    Asia Pac Psychiatry; 2016 Dec; 8(4):260-268. PubMed ID: 27787964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?
    Safer DJ
    Pediatrics; 2006 Sep; 118(3):1248-51. PubMed ID: 16951019
    [No Abstract]   [Full Text] [Related]  

  • 13. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
    Dording CM; Mischoulon D; Petersen TJ; Kornbluh R; Gordon J; Nierenberg AA; Rosenbaum JE; Fava M
    Ann Clin Psychiatry; 2002 Sep; 14(3):143-7. PubMed ID: 12585563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-associated somnambulism.
    Lange CL
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):211-2. PubMed ID: 15725964
    [No Abstract]   [Full Text] [Related]  

  • 15. Phenomenology and treatment of agitation.
    Schatzberg AF; DeBattista C
    J Clin Psychiatry; 1999; 60 Suppl 15():17-20. PubMed ID: 10418809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summary of findings from the FDA regulatory science forum on measuring sexual dysfunction in depression trials.
    Kronstein PD; Ishida E; Khin NA; Chang E; Hung HM; Temple RJ; Yang P
    J Clin Psychiatry; 2015 Aug; 76(8):1050-9. PubMed ID: 26335083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
    Perlis RH; Mischoulon D; Smoller JW; Wan YJ; Lamon-Fava S; Lin KM; Rosenbaum JF; Fava M
    Biol Psychiatry; 2003 Nov; 54(9):879-83. PubMed ID: 14573314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.
    Amitai M; Kronenberg S; Carmel M; Michaelovsky E; Frisch A; Brent D; Apter A; Chen A; Weizman A; Fennig S
    J Neural Transm (Vienna); 2016 Nov; 123(11):1347-1354. PubMed ID: 27324805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diaphoresis: A Presentation of Serotonin Syndrome From Vortioxetine.
    Ong CY; Vasanwala FF
    Prim Care Companion CNS Disord; 2018 May; 20(3):. PubMed ID: 29917334
    [No Abstract]   [Full Text] [Related]  

  • 20. Sildenafil as treatment for antidepressant-induced sexual dysfunction.
    Harinstein L
    JAMA; 2008 Nov; 300(20):2365; author reply 2365-6. PubMed ID: 19033582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.